Loss of CD10/NEP Expression in the Pulmonary Carcinogenesis

Abstract

Insights

Loss of CD10/neutral endopeptidase 24.11 (NEP) expression in lung cancer cells may drive pulmonary carcinogenesis. This loss is topographically linked to non-small cell lung carcinoma (NSCLC) proliferation, particularly in squamous cell types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • CD10/neutral endopeptidase 24.11 (NEP) is a cell surface metalloproteinase modulating peptide hormone responses.
  • CD10/NEP influences peptide-mediated proliferation in lung carcinomas and airway epithelium.

Purpose of the Study:

  • To evaluate CD10/NEP expression in non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC).
  • To correlate CD10/NEP expression with clinicopathologic parameters and proliferative activity.

Main Methods:

  • Immunohistochemistry used to assess CD10/NEP and Ki-67 expression in 55 NSCLC and SCLC specimens.
  • Chi-square or Fisher's exact tests analyzed correlations between CD10/NEP, Ki-67, and clinicopathologic parameters.

Main Results:

  • Most NSCLC (76%) and SCLC (80%) cases exhibited loss of CD10/NEP expression in tumor cells.
  • CD10/NEP expression was strong in normal bronchial/alveolar epithelia and stromal fibroblasts.
  • CD10/NEP expression showed no correlation with proliferative activity or most clinicopathologic parameters, except age.

Conclusions:

  • Loss of CD10/NEP expression may play a role in pulmonary carcinogenesis for both NSCLC and SCLC.
  • Topographical CD10/NEP expression is inversely correlated with NSCLC proliferative activity, especially in squamous cell carcinoma.